Table S1. List of Primers

Primer sequences for cloning of the chimeric construct Il2-Ra /cytoplasmic tail of ADAM15	
Primer I	5' GGATCCGTCAGGAAGATGGATTCATACCTG 3'
Primer II	5' TGAGGAGCAGCCCTGTGGTCTGGTACTCTGTTGTAAATATGGACGT 3'
Primer III	5' ACCACAGG GCTGCTCCTCAG 3'
Primer IV	5' CTCGAGGTCG ACGGTATCGA 3'

Primer sequences for cloning ADAM15, FAK and src constructs for mammalian two-hybrid	
ADAM15 (cytoplasmic tail)	5' AGGATCCATGTACCGTGCCCGCCTGCACCA 3' 5' TGCGGCCGCCTAGAGGTAGAGCGAGGACACTGT 3'
FAK 33-355	5' TAGGATCCGGTGCAATGGAGCGAGTATTAAAG 3' 5' TTGCGGCCGCCTACGAGGTTCCATTCACCAGC 3'
FAK 422-676	5' AGGATCCATAGAACTTG GACGATGTATTGGAGAAG 3' 5' AGCGGCCGCCTAGAGCTGAGCTTTAAGTTCAGTAAACC 3'
FAK 707-1052	5' TAGGATCCGGGTCTGATGAAGCACCGCCCAA 3' 5' TGCGGCCGCCTAGTGTGGTCTCGTCTGCCCAAGCA 3'
FAK 707-913	5' TAGGATCCGGGTCTGATGAAGCACCGCCCAA 3' 5' TGCGGCCGCCTAAGGAGGGGGGCTGATTTCCTG 3'
FAK 914-1052	5' AGGATCCACTGCCAACCTGGACCGGTCG 3' 5' TGCGGCCGCCTAGTGTGGTCTCGTCTGCCCAAGCA 3'
FAK 707-850	5' TAGGATCCGGGTCTGATGAAGCACCGCCCAA 3' 5' TGCGGCCGCTTTCCAATCGGACCCTGAAGACT 3'
FAK 707-770	5'TAGGATCCGGGTCTGATGAAGCACCGCCCAA 3' 5' AGCGGCCGCGTCCAAAAGAGATGCCTGACCT 3'
FAK 730-790	5' AGGATCCTATCCCAGCCCACAGCACATGGT 3' 5' AGCGGCCGCCTAGTCCTCCACATTGGGCTGCCAC 3'
FAK 730-775	5' AGGATCCTATCCCAGCCCACAGCACATGGT 3' 5' AGCGGCCGCCTAATTCCATGAATCTGTTTGGACCTGG 3'
FAK 740-790	5' AGGATCCAATCATTACCAGGTTTCTGGCTACCC 3' 5' AGCGGCCGCCTAGTCCTCCACATTGGGCTGCCAC 3'
FAK 750-850	5' TGGATCCTCACATGGAATCACAGCCATGGCT 3' 5' AGCGGCCGCCTAACTTCCATCCTCCCTGTCAATACTG 3'
FAK 770-850	5' AGGATCCTAGACCTCAGGAGATAGCAATGTGG 3' 5' AGCGGCCGCCTAACTTCCATCCTCCCTGTCAATACTG 3'
Src (1-192)	5' TGGATCCATGTCAGCAATACAGGCCGCCT 3' 5' TGCGGCCGCTCACATGTTCAGGGCCCAGCCGCT 3'
full length Src (1-450)	5' TGGATCCATGTCAGCAATACAGGCCGCCT 3' 5' TGCGGCCGCTCACAGGTGCAGCTCGTGGGTT 3'

Fig. S1


300
ADAM15-transfected
FITC-A
10^2
10^3
10^4
10^5
Fluorescence intensity
300
ADAM15 minus cytoplasmic domain
FITC-A
10^2
10^3
10^4
10^5
Fluorescence intensity

Figure S2


ADAM15-transfected
OA patients
kDa
a
b
1
2
3
4
5
6
7
8
200
150
90
72
43
34
ADAM15
GAPDH
ADAM15-transfected
OA patients
kDa
a
b
9
10
11
12
13
14
15
200
150
90
72
43
34
ADAM15
GAPDH

Table S1. **Primer sequences used for cloning the chimeric IL2rα and ADAM15, FAK, Src constructs for mammalian two-hybrid.**

Figure S1. **Surface expression of full-length and mutant ADAM15 by FACS analysis.** ADAM15- and ADAM15Δcyto-transfected T/C28a4 chondrocytes were stained with mouse anti ADAM15 antibodies, and following with FITC conjugated anti mouse IgG and subjected to Flow cytometry (BD FACS Canto II, Becton Dickinson). Open histograms depict the number of cells stained with the ADAM15 antibody, grey histograms show results obtained with the secondary antibody as a negative control. ADAM15-transfected cells display slightly lower ADAM15 cell surface expression (46.0 ± 4.0) than ADAM15Δcyto- transfected cells (59.6 ± 2.2). Results shown are representative from 3 different experiments performed in triplicates.

Figure S2. **ADAM15 expression in OA chondrocytes**. Lysates of ADAM15-transfected T/C28a4 cells (a, 20µg; b, 40µg) and human osteoarthritic chondrocytes derived from patients that underwent joint replacement surgery (donors 1, 2, 9-11 < 10µg; lanes 3, 8; 20 µg; donors 4-7, 12, 13; 40µg) were subjected to SDS/PAGE under nonreducing conditions and subsequent immunoblotting. ADAM15 protein expression was detected using mouse anti ADAM15 antibodies (recognizing the prodomain, amino acids 1-200). The majority of the lysates from the OA samples possesses markedly higher amounts of ADAM15 as compared to the ADAM15-transfected T/C28a4 chondrocytes.